Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...

Novo Nordisk ($NVO) lost nearly $100 billion in market cap in one session and pointed fingers at Hims & Hers Health ($HIMS) ...

Danish leader will face a challenging landscape among competitors ...

Health Hims & Hers Will Sell Wegovy-Like Weight Loss Drugs for $199 The telehealth company's stock surged after the announcement Bruce Gil, Quartz Published May 20, 2024 | Comments (13) 𝕏 ...

Hims & Hers says its GLP-1 medications contain the same active ingredients as its rivals, but the price starts at $199 per month. For comparison, Wegovy costs around $1,350 per month, and Ozempic ...

Hims & Hers Health, Inc. HIMS announced that eligible customers can now access six months of prescription-only Wegovy at a new, affordable price. The company, via this offer, aims to make proven ...

Should you buy HIMS stock at $57?Lofty Valuations HIMS stock is deemed expensive by most metrics. The company trades at 6.6 times its sales, which is more than double the S&P 500’s 3.0 ratio ...

On Tuesday, Hims & Hers announced a long-term collaboration with Denmark-based Novo Nordisk A/S (NVO), which makes Wegovy and diabetes-treatment Ozempic, which are both approved by the FDA.